



DATE: August 24, 2023
TO: Commonwealth of Kentucky Medicaid Pharmacy Network
FROM: MedImpact Healthcare Systems
Subject: GLP-1 Agonist Soft Edit

Status: Please be advised, the Department for Medicaid Services (DMS) has made the following change to concurrent use of the glucagon-like peptide-1 (GLP-1) agonist and dipeptidyl peptidase-4 (DPP-4) inhibitor drug classes. A claim for a GLP-1 agonist (i.e., Ozempic, Trulicity, Mounjaro, etc.) will be denied if there is an active DPP-4 inhibitor (i.e., Januvia, Tradjenta, etc.) claim for the same member. Similarly, a claim for a DPP-4 inhibitor will be denied if there is an active GLP-1 inhibitor claim for the same member.

- The reject message will read "GLP-1 & DPP-4 CONC USE, SUBMIT PPS CODES".
- The DUR messaging will read "DUPLICATE THERAPY, SUBMIT PPS CODES: 439-E4 =TD; 440-E5 =M0, MR, PH, P0, R0; 441-E6= 1A, 1B, 1G".

In both instances, the denial can be overridden at point-of-sale by entering professional pharmacy services (PPS) codes as seen in the chart below. This change went into effect on **August 11th, 2023**.

NCPDP Field #	PPS Code Value & Description
439-E4	Select the following option: <ul style="list-style-type: none">• TD = therapeutic duplication
440-E5	Select one of the following options: <ul style="list-style-type: none">• M0 = prescriber consulted• MR = medication review• PH = patient medication history• P0 = patient consulted• R0 = pharmacist consulted other source
441-E6	Select one of the following options: <ul style="list-style-type: none">• 1A = filled as is, false positive• 1B = filled prescription as is• 1G = filled with prescriber approval



Products Impacted

GLP-1 Agonists

Adlyxin, Bydureon, Byetta, Mounjaro, Ozempic, Rybelsus, Soliqua, Trulicity, Victoza, Xultophy

DPP-4 Inhibitors

alogliptin, alogliptin-metformin, alogliptin-pioglitazone, Glyxambi, Janumet, Janumet XR, Januvia, Jentadueto, Jentadueto XR, Kazano, Kombiglyze XR, Nesina, Onglyza, Oseni, Qtern, Steglujan, Tradjenta, Trijardy XR

Frequently Asked Questions

Why was this change implemented?	The concurrent use of a GLP-1 agonist and a DPP-4 inhibitor is not an American Diabetes Association recommended therapy as the mechanisms of action are similar.
What is the expected duration of use of this override for a member?	Use of PPS codes to override the edit is expected to occur for a maximum of one to two months to allow a member to taper off one medication therapy.
What if the prescriber wants a member on a GLP-1 agonist and DPP-4 inhibitor concurrently?	Pharmacists should use professional judgment to continue addressing prospective DUR rejections by reviewing and submitting PPS codes when applicable. Adequate documentation is encouraged.

MedImpact Contact Information:

Program Questions	KYMCOPBM@MedImpact.com
Pharmacy Help Desk	(800) 210-7628 [24 hours per day/ 7 days per week]
Prior Authorizations	Phone (844) 336-2676 [8:00AM - 7:00PM EST/ 7 days per week]; Fax (858) 357-2612
Pharmacy Portal	https://kyportal.medimpact.com/
BIN: 023880 / PCN: KYPROD1 / GROUP: KYM01	